Excerpt

The purpose of the workshop was to convene representatives from a variety of voluntary health organizations with experience in establishing and developing translational research programs supported by venture philanthropy strategies. Participants provided valuable insight into a wide range of considerations for other voluntary health organizations who are seeking to start or develop their translational research programs. Discussions centered on best practices and lessons learned in order to improve efficiency and effectiveness in translational research.

Contents

• The National Academies
• Workshop on Venture Philanthropy Strategies to Support Translational Research Planning Committee
• Forum on Neuroscience and Nervous System Disorders
• Independent Report Reviewers
• Introduction
  • VENTURE PHILANTHROPY
  • TRANSLATIONAL RESEARCH
  • ABOUT THE FORUM AND THE WORKSHOP
• 1. Getting Started in Translational Research
  • KNOW YOUR DISEASE
  • KNOW YOURSELF
  • KNOW YOUR PARTNERS
  • IDENTIFY YOUR GOAL
  • PREPARATION NEVER STOPS
• 2. Models for Building a Translational Research Program
  • APPROACHING SCIENTIFIC DISCOVERY
  • LEADERSHIP
  • FUNDING MODELS
• 3. Legal, Accounting, and Process Issues
  • SOCIAL ACCOUNTING
  • LEGAL ISSUES
• 4. Partnerships, Data Sharing, and Intellectual Property
  • PARTNERSHIPS
  • DATA SHARING
  • MANAGING INTELLECTUAL PROPERTY
• 5. Communications
  • INSTEAD OF MANAGING EXPECTATIONS, LEAD
  • ACTING VERSUS REACTING
  • EDUCATION
  • LISTENING
  • TOOLS
• Conclusion
  • THE TRANSLATIONAL RESEARCH GAP
  • FROM PUBLIC TO PRIVATE
  • THE DOUBLE BOTTOM LINE
• Appendixes
  • A References
  • B Workshop on Venture Philanthropy Strategies Used by Patient Organizations to Support Translational Research
  • C Workshop Attendees
  • D Biographical Sketches of Invited Speakers, Planning Committee Members, and Staff

Sarah Hanson, Lori Nadig, and Bruce Altevogt, Rapporteurs.

This project was supported by contracts between the National Academy of Sciences and the Alzheimer’s Association; AstraZeneca Pharmaceuticals, Inc.; CeNeRx Biopharma; the Department of Health and Human Services’ National Institutes of Health (NIH, Contract No. N01-OD-4-213) through the National Eye Institute, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, the NIH Blueprint for Neuroscience Research; Eli Lilly and Company; GE Healthcare, Inc.; GlaxoSmithKline, Inc.; Johnson & Johnson Pharmaceutical Research and Development, Inc.; Merck Research Laboratories, Inc.; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. OIA-0753701); the Society for Neuroscience; and Wyeth Research, Inc.

Suggested citation:

IOM (Institute of Medicine). 2009. Venture philanthropy strategies to support translational research: Workshop summary. Washington, DC: The National Academies Press.

The views presented in this publication are those of the editors and attributing authors and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.